Invasive pneumococcal surveillance to assess the potential benefits of extended spectrum conjugate vaccines (PCV15/PCV20) in older adults

被引：2
|
作者：
Humphreys, Hilary [1 ]
Corcoran, Mary [1 ,2 ]
Mereckiene, Jolita [4 ]
Cunney, Robert [1 ,2 ,3 ]
Cotter, Suzanne [4 ]
机构：
[1] Ireland Univ Med & Hlth Sci, Royal Coll Surg, Dept Clin Microbiol, Dublin, Ireland
[2] Childrens Hlth Ireland Temple St, Irish Meningitis & Sepsis Reference Lab, Dublin, Ireland
[3] Childrens Hlth Ireland Temple St, Dept Microbiol, Dublin, Ireland
[4] Hlth Protect Surveillance Ctr, Hlth Serv Execut, Dublin, Ireland
来源：
EPIDEMIOLOGY AND INFECTION | 2023年 / 151卷
基金：
欧盟地平线“2020”;
关键词：
Conjugated vaccines; elderly; invasive pneumococcal disease; PCV13; PCV15; PCV20; PPV23; serotypes; strategy; STREPTOCOCCUS-PNEUMONIAE; DISEASE; IMMUNOGENICITY; IRELAND; SAFETY;
D O I：
10.1017/S0950268823000110
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
The introduction of pneumococcal conjugate vaccines (PCV) into the childhood vaccination programme has reduced invasive pneumococcal disease (IPD). Although anticipated from data elsewhere, surveillance in Ireland has confirmed reductions in IPD amongst those > 65 years of age due to a decline of PCV serotypes in this age group. Currently, direct protection against IPD in the elderly is focused on immunisation with the 23-valent pneumococcal polysaccharide vaccine (PPV23). However, immunity may not be as effective as with PCV and, furthermore, PPV23 uptake is poor in Ireland. Hence, consideration should be given to providing a PCV to this age group.
引用
收藏
页数：4
相关论文
共 13 条
  • [1] An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population
    Fridh, Ann-Charlotte
    Palmborg, Andreas
    Ta, An
    Freigofaite, Donata
    Warren, Sophie
    Perdrizet, Johnna
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [2] PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
    Chapman, Timothy J.
    Olarte, Liset
    Dbaibo, Ghassan
    Houston, Avril Melissa
    Tamms, Gretchen
    Lupinacci, Robert
    Feemster, Kristen
    Buchwald, Ulrike K.
    Banniettis, Natalie
    [J]. EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 137 - 147
  • [3] Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age
    Kanevsky, Isis
    Surendran, Naveen
    McElwee, Kathleen
    Lei, Lanyu
    Watson, Wendy
    Pride, Michael
    Scully, Ingrid
    Karauzum, Hatice
    Anderson, Annaliesa
    Young, Mariano
    [J]. VACCINE, 2023, 41 (45) : 6625 - 6629
  • [4] Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children
    Ryman, Josiah
    Sachs, Jeffrey R.
    Yee, Ka Lai
    Banniettis, Natalie
    Weaver, Jessica
    Weiss, Thomas
    [J]. EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 60 - 68
  • [5] Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20
    Schellenberg, John J.
    Adam, Heather J.
    Baxter, Melanie R.
    Karlowsky, James A.
    Golden, Alyssa R.
    Martin, Irene
    Demczuk, Walter
    Mulvey, Michael R.
    Zhanel, George G.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 : I37 - I47
  • [6] Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
    Hurley, Donald
    Griffin, Carl
    Young, Mariano, Jr.
    Scott, Daniel A.
    Pride, Michael W.
    Scully, Ingrid L.
    Ginis, John
    Severs, Joseph
    Jansen, Kathrin U.
    Gruber, William C.
    Watson, Wendy
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E1489 - E1497
  • [7] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
    Stacey, Helen L.
    Rosen, Jeffrey
    Peterson, James T.
    Williams-Diaz, Angela
    Gakhar, Vanita
    Sterling, Tina M.
    Acosta, Camilo J.
    Nolan, Katrina M.
    Li, Jianing
    Pedley, Alison
    Benner, Patrice
    Abeygunawardana, Chitrananda
    Kosinski, Michael
    Smith, William J.
    Pujar, Hari
    Musey, Luwy K.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 530 - 539
  • [8] UPTAKE OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV20) AMONG UNITED STATES (US) ADULTS FOLLOWING 2022 UPDATE TO RECOMMENDATIONS
    Averin, A.
    Vietri, J.
    Mohs, Arguedas A.
    Kaliasethi, A.
    Willis, S. J.
    Lonshteyn, A.
    Weycker, D.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S166 - S166
  • [9] Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen
    Ryman, Josiah
    Sachs, Jeffrey R.
    Banniettis, Natalie
    Weiss, Thomas
    Ahsman, Maurice
    Yee, Ka Lai
    Weaver, Jessica
    [J]. EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 467 - 473
  • [10] Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain
    Cantarero, David
    Ocana, Daniel
    Onieva-Garcia, Maria Angeles
    Rodriguez-Garcia, Juan
    Galvez, Paulina
    Mendez, Cristina
    Crespo, Carlos
    de Aldecoa, Alejandra lopez-Ibanez
    [J]. VACCINE, 2023, 41 (36) : 5342 - 5349
12